- Home
- JBGS vs HROW Comparison
JBGS vs HROW Comparison
Compare JBGS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- HROW
- Stock Information
- Founded
- JBGS 2016
- HROW 1998
- Country
- JBGS United States
- HROW United States
- Employees
- JBGS N/A
- HROW N/A
- Industry
- JBGS Real Estate Investment Trusts
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- JBGS Real Estate
- HROW Health Care
- Exchange
- JBGS Nasdaq
- HROW Nasdaq
- Market Cap
- JBGS 1.4B
- HROW 1.4B
- IPO Year
- JBGS 2017
- HROW N/A
- Fundamental
- Price
- JBGS $21.17
- HROW $38.51
- Analyst Decision
- JBGS Sell
- HROW Strong Buy
- Analyst Count
- JBGS 2
- HROW 7
- Target Price
- JBGS $16.00
- HROW $64.67
- AVG Volume (30 Days)
- JBGS 1.1M
- HROW 668.1K
- Earning Date
- JBGS 10-28-2025
- HROW 08-11-2025
- Dividend Yield
- JBGS 3.29%
- HROW N/A
- EPS Growth
- JBGS N/A
- HROW N/A
- EPS
- JBGS N/A
- HROW N/A
- Revenue
- JBGS $513,301,000.00
- HROW $227,661,000.00
- Revenue This Year
- JBGS N/A
- HROW $46.17
- Revenue Next Year
- JBGS $2.33
- HROW $39.97
- P/E Ratio
- JBGS N/A
- HROW N/A
- Revenue Growth
- JBGS N/A
- HROW 47.69
- 52 Week Low
- JBGS $13.28
- HROW $20.85
- 52 Week High
- JBGS $22.45
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- JBGS 63.32
- HROW 62.62
- Support Level
- JBGS $20.20
- HROW $37.09
- Resistance Level
- JBGS $20.96
- HROW $39.70
- Average True Range (ATR)
- JBGS 0.49
- HROW 2.37
- MACD
- JBGS 0.03
- HROW 0.08
- Stochastic Oscillator
- JBGS 92.34
- HROW 87.80
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.